Randomized phase 3, multicenter, open-label study comparing evofosfamide (Evo) in combination with doxorubicin (D) vs. D alone in patients (pts) with advanced soft tissue sarcoma (STS): Study TH-CR-406/SARC021

@inproceedings{Tap2016RandomizedP3,
  title={Randomized phase 3, multicenter, open-label study comparing evofosfamide (Evo) in combination with doxorubicin (D) vs. D alone in patients (pts) with advanced soft tissue sarcoma (STS): Study TH-CR-406/SARC021},
  author={William D. Tap and Zsuzsanna P{\'a}pai and Brian A. Van Tine and Steven Attia and Kristen N Ganjoo and Robin L Jones and Scott Michael Schuetze and Damon R Reed and Shanta Chawla and Richard F. Riedel and Anders Krarup-Hansen and Antoine Italiano and Peter Hohenberger and Giovanni Grignani and Lee Cranmer and Thierry Alcindor and Antonio L{\'o}pez-pousa and Tillman E. Pearce and Stew Kroll and Patrick Sch{\"o}ffski},
  year={2016}
}